BLRX BioLineRx Ltd.

2.31
+0.27  (+13%)
Previous Close 2.04
Open 1.99
Price To Book 0.62
Market Cap 24,303,175
Shares 10,520,855
Volume 254,332
Short Ratio
Av. Daily Volume 108,837
Stock charts supplied by TradingView

NewsSee all news

  1. BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer

    TEL AVIV, Israel, Dec. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today preliminary data from the triple

  2. BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York

    TEL AVIV, Israel, Nov. 26, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will host an investor breakfast

  3. BioLineRx Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    TEL AVIV, Israel, Nov. 11, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended

  4. BioLineRx to Report Third Quarter 2019 Results on November 11, 2019

    TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results

  5. BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients

    TEL AVIV, Israel, Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today results of a Phase 2b trial assessing the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b/2 data due late 2019 or early 2020.
BL-8040 in combination with TECENTRIQ (atezolizumab)
Non-small cell lung cancer (NSCLC)
Phase 1/2 initiation announced October 18, 2017.
BL-8040 and atezolizumab
Gastric Cancer
Phase 2 data presented at EHA June 15, 2018.
BL-8040
Stem-cell mobilization for allogeneic transplantation
Phase 1/2 initiation announced September 26, 2017.
BL-8040 in combination with atezolizumab - BATTLE
Acute myeloid leukemia (AML)
Phase 2 data released December 5, 2019 noted 4/15 partial responses. Updated data due at ESMO-IO, December 13, 2019 with PFS data due mid-2020.
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Phase 2b interim data due 1H 2020.
BL-8040
Consolidation treatment for AML cancer patients
Phase 3 top-line data due 2H 2020.
BL-8040 GENESIS
Stem-cell mobilization for autologous transplantation
Phase 2 data released March 2016. Full set of data presented September 8, 2016
BL-8040
Acute myeloid leukemia (AML) cancer relapsed and refractory
Phase 1/2 (part 2) data due by end of 2020.
AGI-134
Solid tumors
Phase 1b/2 data due late 2019 or early 2020.
BL-8040 in combination with TECENTRIQ (atezolizumab) and PEGPH20
Pancreatic cancer
Phase 2a data to be presented at ESMO December 13, 2019.
BL-8040 in combination with KEYTRUDA
Pancreatic cancer

Latest News

  1. BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer

    TEL AVIV, Israel, Dec. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today preliminary data from the triple

  2. BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York

    TEL AVIV, Israel, Nov. 26, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will host an investor breakfast

  3. BioLineRx Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    TEL AVIV, Israel, Nov. 11, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended

  4. BioLineRx to Report Third Quarter 2019 Results on November 11, 2019

    TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results

  5. BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients

    TEL AVIV, Israel, Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today results of a Phase 2b trial assessing the

  6. BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment

    TEL AVIV, Israel, Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further elucidating

  7. BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019

    TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will deliver the following poster

  8. BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

    TEL AVIV, Israel, Sept. 25, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today dosing of the first patient in part 2

  9. BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

    TEL AVIV, Israel, Sept. 3, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it has successfully completed the